# US 8,278,292 B2 · Therapeutic compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,292 B2
- Document ID: US8278292B2
- Status: Granted
- Kind: B2
- Application number: 12/097,258
- Filed: 2006-12-18
- Published: 2009-11-26
- Granted: 2012-10-02
- Earliest claimed: 2005-12-16
- Assignees: LEO Laboroatories Limited
- Inventors: Marc Barry Brown; Michael Edward Donald Crowthers; Tahir Nazir
- Web page: https://patentgrep.com/patent/US8278292B2

## CPC

- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/215: of carboxylic acids
- A61K 36/47: Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.

## Claims

### Claim 1

A pharmaceutical formulation of ingenol-3-angelate (isoform ‘b’), said pharmaceutical formulation comprising ingenol-3-angelate (isoform ‘b’) and a pharmaceutically acceptable solvent, said pharmaceutical formulation further comprising a pharmaceutically acceptable acidifying agent, wherein said pharmaceutical formulation retains at least about 95% of said ingenol-3-angelate (isoform ‘b’) after twelve months of storage at a temperature within the range of about 2° C. to about 8° C.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1, wherein said solvent is selected from the group consisting of polyethylene glycol, methyl ethyl ketone, ethyl acetate, diethyl ether, benzyl alcohol, and mixtures thereof.

### Claim 3 (depends on 1)

The pharmaceutical formulation of claim 1, wherein said solvent consists essentially of benzyl alcohol.

### Claim 4 (depends on 1)

The pharmaceutical formulation of claim 1, wherein said acidifying agent is an acid buffer.

### Claim 5 (depends on 4)

The pharmaceutical formulation of claim 4, wherein said acid buffer is a citrate or phosphate buffer.

### Claim 6 (depends on 1)

The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation comprises:
a) isopropyl alcohol;
b) hydroxyethylcellulose;
c) benzyl alcohol; and
d) citrate buffer.

### Claim 7 (depends on 1)

The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation retains at least 97.5% of said ingenol-3-angelate (isoform ‘b’) after twelve months of storage at a temperature within the range of about 2° C. to about 8° C.

### Claim 8 (depends on 1)

The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation retains at least 99.0% of said ingenol-3-angelate (isoform ‘b’) after twelve months of storage at a temperature within the range of about 2° C. to about 8° C.

### Claim 9 (depends on 1)

The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation retains at least 97.5% of said ingenol-3-angelate (isoform ‘b’)
after three months of storage at a temperature within the range of about 2° C. to about 8° C.

### Claim 10 (depends on 1)

The pharmaceutical formulation of claim 1, wherein said pharmaceutical formulation retains at least 99.0% of said ingenol-3-angelate (isoform ‘b’)
after three months of storage at a temperature within the range of about 2° C. to about 8° C.

### Claim 11

A pharmaceutical formulation of ingenol-3-angelate (isoform ‘b’), said pharmaceutical formulation comprising ingenol-3-angelate (isoform ‘b’) and a pharmaceutically acceptable solvent, said pharmaceutical formulation further comprising a pharmaceutically acceptable acidifying agent, wherein said pharmaceutical formulation retains at least about 95% of said ingenol-3-angelate (isoform ‘b’) after two weeks of storage at about 25° C.

### Claim 12 (depends on 11)

The pharmaceutical formulation of claim 11, wherein said pharmaceutical formulation retains at least 97.5% of said ingenol-3-angelate (isoform ‘b’) after two weeks of storage at about 25° C.

### Claim 13 (depends on 11)

The pharmaceutical formulation of claim 11, wherein said pharmaceutical formulation retains at least 98.5% of said ingenol-3-angelate (isoform ‘b’) after two weeks of storage at about 25° C.

### Claim 14

A pharmaceutical formulation of ingenol-3-angelate (isoform ‘b’), said pharmaceutical formulation comprising ingenol-3-angelate (isoform ‘b’) and a pharmaceutically acceptable solvent, said pharmaceutical formulation further comprising a pharmaceutically acceptable acidifying agent, wherein said pharmaceutical formulation retains at least about 95% of said ingenol-3-angelate (isoform ‘b’) after four weeks of storage at about 40° C.

### Claim 15

A pharmaceutical formulation of ingenol-3-angelate (isoform ‘b’), said pharmaceutical formulation comprising ingenol-3-angelate (isoform ‘b’) and a pharmaceutically acceptable solvent, said pharmaceutical formulation further comprising a pharmaceutically acceptable acidifying agent, wherein said pharmaceutical formulation retains at least about 95% of said ingenol-3-angelate (isoform ‘b’) after two weeks of storage at about 40° C.

### Claim 16 (depends on 15)

The pharmaceutical formulation of claim 15, wherein said pharmaceutical formulation retains at least 97.5% of said ingenol-3-angelate (isoform ‘b’) after two weeks of storage at about 40° C.

### Claim 17 (depends on 1, 11, 14)

The pharmaceutical formulation of any one of claims 1, 11, 14, or 15, wherein said pharmaceutical formulation is a gel.

### Claim 18 (depends on 1, 11, 14)

The pharmaceutical formulation of any one of claims 1, 11, 14, or 15, wherein said acidifying agent is an organic acid.
